Abstract View

Author(s): Ghanchi Sujan*1, Patel Dhara2, Patel Grishma3, Dhananjay Meshram4

Email(s): 1sujanghanchi29@gmail.com

Address:

    Department of Pharmaceutical Quality Assurance, Pioneer pharmacy college, Vadodara, Gujarat, India

Published In:   Volume - 5,      Issue - 5,     Year - 2026

DOI: https://doi.org/10.71431/IJRPAS.2026.5522  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Preventing contamination is one of many key factors when making pharmaceuticals because any type of contamination would negatively affect the safety, quality, and effectiveness of pharmaceutical products and the health of the people using those products. Pharmaceutical Contamination can occur as a result of microbes, particulate matter, chemicals, endotoxins, and cross-contamination from a number of sources, including manufacturers (staff), materials (raw), utilities (electricity, water, etc.), equipment (machinery) and the manufacturing environment (cleanroom).Controlling the sources of contamination within a pharmaceutical manufacturer is necessary in order to maintain the integrity of product and to achieve consistent manufacturing operations. Due to the necessitated need to minimize contamination risks and meet regulatory standards, manufacturers of pharmaceuticals must develop a Contamination Control Strategy (CCS). A well-designed CCS incorporates multiple levels of control throughout the entire manufacturing process in order to provide for product quality and regulatory compliance. The CCS shall also be in alignment with appropriate regulatory requirements such as cGMP, ICH guidelines Q9, Q10, regulations found within the EU cGMP Annex 1, FDA guidance documents, WHO guidelines, and ISO guidelines.

Cite this article:
Ghanchi Sujan, Patel Dhara, Patel Grishma, Dhananjay Meshram. Contamination Control Strategy Development in Pharmaceutical Manufacturing. IJRPAS, May 2026; 5(5): 368-395.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2026.5522


References not available.

Related Images:



Recent Images



Evaluation of In-Vitro Anti-Diabetic Activity And   Antioxidant Activity In Ethanolic and Hydroalcoholic Extract of leaves of Gymnema Sylvestre
Molecular Docking Approaches in Antibacterial Drug Discovery: Computational Insights into Natural Compounds
In-vitro Evaluation of Anti-Urolithiatic Activity of Hydroalcoholic Extract of Centella asiatica Leaves
Quality by Design (Qbd) Based Method Development and Validation of Trelagliptin Succinate byu RP-HPLC.
Cubosomes: Structure, Preparation Methods, Characterization, and Pharmaceutical Applications
Programmable Oral Drug Delivery Systems: Materials, Device Engineering, Stimuli-Responsive Mechanisms, and Clinical Translation
Biomimetic Nanocarrier for Targeted Drug Delivery: An Integrated Review
From Phosphate Wasting to Targeted Therapy: An Updated Review of FGF23-Mediated Hypophosphatemic Rickets
Nanotechnology-Based Drug Delivery Systems for Alzheimer’s Disease: Emerging Strategies for Blood–Brain Barrier Targeting
Explainable AI in Pharmacy: Building Trust in AI-Based Drug Recommendation

Tags